Latest Conference Articles

Experts at Asembia’s AXS25 Summit discussed the economics of specialty pharmacy for rare diseases, addressing high treatment costs and strategies for balancing innovation.

Integrating community pharmacists into specialty pharmacy care can enhance patient access, address physician shortages, and expand pharmacists' roles in delivering high-quality clinical services, according to experts at Asembia’s AXS25 Summit.

Acneiform rash is a common adverse effect of EGFR-targeting therapies.

Dostarlimab in the neoadjuvant setting yielded a 100% clinical complete response in patients with rectal cancer.

A phase 2 trial showed that using ctDNA to guide adjuvant pembrolizumab therapy after surgery effectively cleared minimal residual disease and reduced recurrence in patients with resected mismatch repair-deficient (dMMR) solid tumors.

The study found that 4 weeks was the ideal time point to test for cTDNA.

Certain antibiotics may have a more significant impact on CAR T-cell efficacy and toxicity.

AI may help to accurately classify pediatric sarcoma subtypes using digitized pathology images, potentially improving diagnosis and treatment accessibility across diverse health care settings.

Interim results from the phase 1 SENTI-202-101 trial show that SENTI-202, a logic-gated, off-the-shelf chimeric antigen receptor natural killer (CAR NK) cell therapy, achieved complete remission in 4 patients with relapsed or refractory (R/R) acute myeloid leukemia (AML).

Pretrained foundation machine learning models significantly improved the accuracy of diagnosing non-melanoma skin cancer from digital pathology images and may offer a practical, resource-efficient solution for cancer diagnosis in underserved settings.

Zoldonrasib, a novel oral KRAS G12D-selective inhibitor, demonstrated promising safety and early antitumor activity in patients with previously treated non–small cell lung cancer (NSCLC), offering a potential new targeted therapy for this underserved population.

Logan Schneider, MD, explains the latest findings on narcolepsy and idiopathic hypersomnia treatments, highlighting patient experiences and sleep architecture improvements.

The Asembia AXS25 Summit will include the latest news and expert insights in the specialty pharmacy field.

This alternative to IV infusion reduces patient treatment times and eases providers’ operational burdens.

Ginger Blackmon, PharmD, explains how NCODA’s Positive Quality Interventions (PQIs) help improve oncology care by guiding best practices, supporting teamwork, and streamlining workflows.

Philip Kuball, MD, neurology resident at NYU Langone Health, highlights the integral role of pharmacists in monitoring patient eligibility, managing dosing schedules, and ensuring safe medication interactions for lecanemab treatment in Alzheimer disease.

Lauren B. Krupp, MD, FAAN, provides comprehensive guidance on treating pediatric multiple sclerosis, emphasizing early intervention, high-efficacy therapies, and holistic family support.

The 2025 SPPCP Virtual Conference on Tuesday, May 20, 2025, will offer pharmacists and clinicians a full day of CE-accredited sessions on complex pain management, opioid use disorder, mentorship, and innovative approaches in palliative care, with opportunities for networking and professional development.

Lepodisiran, a small interfering RNA, demonstrated cholesterol-lowering effects at 16-mg, 96-mg, and 400-mg doses, with the highest dose being the most effective.

Iman Ahmed, PharmD, BCOP, shared key insights about how social determinants of health impact treatment access and outcomes for patients with leukemia.

Zahra Mahmoudjafari, PharmD, BCOP, FHOPA, shared insight from the HOPA Annual Meeting 2025.

Arefa Bacchus, PharmD, shared key insights about the use of POMP therapy in patients with acute lymphoblastic leukemia (ALL).

Monica Sawiris, PharmD, said there were noticeable differences in toxicities between each regimen.

Erin Lexner, PharmD, BCPS, discussed her team’s experience transitioning to outpatient BEAM from inpatient CBV.

Shelby Quinn, PharmD, BCOP shares insights about treatment using osimertinib in early lines.